Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.

Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR.

Am J Epidemiol. 2011 Jun 15;173(12):1429-39. doi: 10.1093/aje/kwr027. Epub 2011 Apr 24. Erratum in: Am J Epidemiol. 2013 Dec 1;178(11):1680.

2.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR.

J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10.

3.

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA.

Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.

4.

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM Jr, Lippman SM, Platz EA, Schenk J.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1507-15. doi: 10.1158/1055-9965.EPI-15-0394. Epub 2015 Aug 12.

5.

The association of fatty acids with prostate cancer risk.

Newcomer LM, King IB, Wicklund KG, Stanford JL.

Prostate. 2001 Jun 1;47(4):262-8.

PMID:
11398173
6.

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.

Am J Epidemiol. 2011 Jun 15;173(12):1419-28. doi: 10.1093/aje/kwq493. Epub 2011 May 3. Erratum in: Am J Epidemiol. 2011 Dec 15;174(12):1425.

7.

Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer.

Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L.

Int J Cancer. 1997 May 16;71(4):545-51.

8.

A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer.

Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ.

Nutr Res. 2011 Jan;31(1):1-8. doi: 10.1016/j.nutres.2011.01.002.

PMID:
21310299
9.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1484-93. doi: 10.1158/1055-9965.EPI-13-1340.

10.

A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

Liang JA, Sun LM, Lin MC, Chang SN, Sung FC, Muo CH, Kao CH.

Oncologist. 2012;17(7):986-91. doi: 10.1634/theoncologist.2011-0464. Epub 2012 Jun 20.

11.

Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia.

Yang YJ, Lee SH, Hong SJ, Chung BC.

Clin Biochem. 1999 Aug;32(6):405-9.

PMID:
10667474
12.

Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1823-32. doi: 10.1158/1055-9965.EPI-12-0695. Epub 2012 Aug 9.

13.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29.

14.

RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.

McCulloch M, Alvarez E, Gendreau R, Haney S, Harrelson J, Luo R.

J Natl Cancer Inst. 2014 Apr;106(4):dju024. doi: 10.1093/jnci/dju024. Epub 2014 Mar 31. No abstract available.

PMID:
24685926
15.

RE: Serum phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Suburu J, Lim K, Calviello G, Chen YQ.

J Natl Cancer Inst. 2014 Apr;106(4):dju023. doi: 10.1093/jnci/dju023. Epub 2014 Mar 31. No abstract available.

16.

Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Kristal AR, Till C, Platz EA, Song X, King IB, Neuhouser ML, Ambrosone CB, Thompson IM.

Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):638-46. doi: 10.1158/1055-9965.EPI-10-1221. Epub 2011 Feb 18.

17.

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M.

Cancer Prev Res (Phila). 2010 Mar;3(3):279-89. doi: 10.1158/1940-6207.CAPR-09-0188. Epub 2010 Feb 23.

18.

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.

Cancer Causes Control. 2011 Aug;22(8):1121-31. doi: 10.1007/s10552-011-9787-7. Epub 2011 Jun 11.

19.

Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk.

Bassett JK, Severi G, Hodge AM, MacInnis RJ, Gibson RA, Hopper JL, English DR, Giles GG.

Int J Cancer. 2013 Oct 15;133(8):1882-91. doi: 10.1002/ijc.28203. Epub 2013 May 9.

20.

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.

Am J Epidemiol. 2008 Dec 15;168(12):1416-24. doi: 10.1093/aje/kwn272. Epub 2008 Oct 21.

Supplemental Content

Support Center